Abstract CN71
Background
Limited information is available on caregiver burden incurred from providing care to pts with advanced cancer. This survey aimed to understand caregiver support reported by pts with mUC.
Methods
Real-world data from the Adelphi Metastatic Urothelial Cancer Disease-Specific Programme were collected from Dec 2020 to Apr 2021. Eligible pts from Eu5 were invited to complete a voluntary questionnaire following physician survey and chart extraction independent of their physician post-consultation. The questionnaire asked pts about their symptoms and caregiver status including relationship to the caregiver, hours spent receiving care, and the type of support received. Descriptive analysis was conducted.
Results
614 pts with mUC and matched chart review data completed the questionnaire with 48% (n=296) reported having ≥1 caregiver. Common symptoms reported by patients with ≥1 caregiver were fatigue (72%), pain (54%), and lack of energy (45%). Partners/spouses were the most common type of caregiver, and pts estimated that professional/paid caregivers spent the most hours per week providing care (Table). The most common support caregivers provided was preparing meals (65%), shopping (65%), traveling out of the home (58%), and planning and organizing pts’ everyday activities (47%).
Conclusions
This multinational, real-world, point-in-time study highlights the role of caregivers in supporting pts with mUC, who often had symptomatic disease. Caregivers dedicate a substantial amount of time supporting pts; this was highest among professional/paid caregivers, indicating that healthcare systems and pts are impacted economically. Further research is needed to examine the economic burden of mUC, including loss of productivity and impact on quality of life, from a caregiver perspective. Table: CN71
| n=296* | ||
| Caregiver type | n (%) | Time, median (IQR),hours per week |
| Partner/spouse | 230 (78) | 15 (15) |
| Child | 95 (32) | 10 (14) |
| Professional caregiver(s) | 24 (8) | 28 (42.2) |
| Other caregiver(s)† | 34 (11) | 10 (12.5) |
*Pts may have had ≥1 caregiver. †Other caregiver(s): friend(s), other relative(s), other nonprofessional caregiver(s), unknown caregiver(s).
Clinical trial identification
Editorial acknowledgement
Editorial support was provided by Hiba Al-Ashtal of ClinicalThinking, and was funded by Pfizer as part of an alliance between Pfizer and Merck (CrossRef Funder ID: 10.13039/100009945).
Legal entity responsible for the study
Pfizer, as part of an alliance between Pfizer and Merck.
Funding
Pfizer, as part of an alliance between Pfizer and Merck (CrossRef Funder ID: 10.13039/100009945).
Disclosure
M. La Puente: Other, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Merck, MSD. R. Montgomery: Other, Personal, Full or part-time Employment, Immediate Family Member That is Employed: AstraZeneca; Other, Personal, Stocks/Shares, Immediate Family Member That has Stock: AstraZeneca. M. Kirker: Financial Interests, Personal and Institutional, Full or part-time Employment: Pfizer; Financial Interests, Personal and Institutional, Stocks/Shares: Pfizer. M. Kearney: Financial Interests, Institutional, Full or part-time Employment: Merck; Financial Interests, Personal, Stocks/Shares: Merck, Novartis Pharma, UCB Biopharma SPRL. N. Costa: Financial Interests, Institutional, Full or part-time Employment: Pfizer; Financial Interests, Personal and Institutional, Stocks/Shares: Pfizer. J. Chang: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer, BMS, Bayer. All other authors have declared no conflicts of interest.